Last reviewed · How we verify
NCT04969211
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Phase 1 trial testing VHX-896 and iloperidone in Healthy in 25 participants. Completed in 13 October 2021.
13 October 2021
Quick facts
| Lead sponsor | Vanda Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 30 June 2021 |
| Primary completion | 13 October 2021 |
| Estimated completion | 13 October 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- VHX-896 and iloperidone — full drug profile →
- Iloperidone and VHX-896 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Vanda Pharmaceuticals — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04969211
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VHX-896 and iloperidone
Trials testing the same drug.
- NCT06494397 — Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Vanda Pharmaceuticals trials
Trials by the same sponsor.
- NCT07446439 — A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use · Phase 3 · recruiting
- NCT06804603 — A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use · Phase 2 · completed
- NCT06701396 — Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant · Phase 3 · recruiting
- NCT06494397 — Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions · Phase 1 · completed
- NCT05903924 — Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04969211 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vanda Pharmaceuticals
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969211.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing